Table of Content
-
Introduction
-
Definition of Global Oncolytic Virus Therapies Market
-
Scope of the Report
-
Methodology
-
Executive Summary
-
Market Overview
-
Market Definition and Segmentation
-
Market Dynamics
-
Drivers
-
Restraints
-
Opportunities
-
Porter's Five Forces Analysis
-
PESTEL Analysis
-
Global Oncolytic Virus Therapies Market, By Commercialized Therapies Outlook
-
Imlygic
-
Oncorine
-
RIGVIR
-
Global Oncolytic Virus Therapies Market, By Pipeline Therapies Outlook
-
Phase I
-
Phase II
-
Phase III
-
Phase IV
-
Global Oncolytic Virus Therapies Market, By Type of Virus Outlook
-
Genetically Engineered Oncolytic Virus
-
Herpes Simplex Virus (HSV)
-
Adenovirus
-
Vaccinia Virus
-
Oncolytic Wild-type Virus
-
Reovirus (respiratory enteric orphan virus)
-
Newcastle Disease Virus (NDV)
-
Vesicular Stomatitis Virus (VSV)
-
Global Oncolytic Virus Therapies Market, By Application Outlook
-
Solid Tumor
-
Breast Cancer
-
Prostate Cancer
-
Lung Cancer
-
Glioblastoma
-
Melanoma
-
Other Applications
-
Hematological Malignancies
-
Lymphoma
-
Leukemia
-
Myeloma
-
Global Oncolytic Virus Therapies Market, By Geography
-
North America
-
United States
-
Canada
-
Europe
-
United Kingdom
-
Germany
-
France
-
Spain
-
Italy
-
Rest of Europe
-
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
Latin America
-
Brazil
-
Mexico
-
Rest of Latin America
-
Middle East & Africa
-
Saudi Arabia
-
United Arab Emirates
-
South Africa
-
Rest of Middle East & Africa
-
Competitive Landscape
-
Company Profiles
-
Amgen, Inc.
-
Company Overview
-
Product Portfolio and Description
-
Key Highlights
-
Financial Overview
-
DAIICHI SANKYO COMPANY, LIMITED
-
DNAtrix
-
Genelux
-
Oncolytics Biotech, Inc.
-
PsiOxus Therapeutics
-
RIGVIR Ltd.
-
Shanghai Sunway Biotech Co., Ltd.
-
SillaJen, Inc.
-
Sorrento Therapeutics, Inc.
-
Takara Bio Inc.
-
Transgene sa
-
VCN Biosciences
-
ViroCure
-
Viralytics Ltd
-
Conclusion and Future Outlook
-
Appendix
-
Research Methodology
-
About the Pharmanucleus
-
Disclaimer